Investigation on application of cycloserine in chemotherapy for multidrug-resistant tuberculosis

Yang LI,Fei WANG,Li-min WU,Min ZHU,Gui-qing HE,Feng SUN,Xiao-meng WANG,Wen-hong ZHANG
DOI: https://doi.org/10.3969/j.issn.1000-6621.2018.02.011
2018-01-01
Abstract:Objective To evaluate the application of cycloserine in the treatment of multidrug-resistant tuberculosis (MDR-TB) and to provide a basis for further optimization of the chemotherapy for MDR-TB patients in China.Methods The clinical data,including treatment outcomes,of 143 MDR-TB patients in Hangzhou Red Cross Hospital and Wenzhou Central Hospital from 2014 to 2016 were collected.All patients received cycloserine-containing standard treatment according to the World Health Organization Treatment Guidelines for Drug-resistant Tuberculosis,2016 Update.The data such as treatment outcome,sputum negative conversion rate,and adverse events associated with drug were summarized.Results Among the 143 patients treated with cycloserine-containing regimen,the overall treatment success rate achieved 69.2% (99/143).81.1% (116/143) of patients had sputum culture conversion in the intensive phase.A total of 13 cases (9.1%,13/143) reported adverse events that were considered to be related with cycloserine,including 7 cases who complained of dizziness or headache,3 cases of limb numbness,2 cases of limb twitch and 1 case of depression.All adverse events were relieved by dose reduction or symptomatic treatment.Conclusion Cycloserine-containing standard therapy has high overall success rate and well tolerance for MDR-TB patients,which is worth to be applied in clinical.
What problem does this paper attempt to address?